| 摘要 |
<p>A Pharmaceutical product comprises an antibody to tumour necrosis factor and an antibody to interferon-η as a combined preparation for simultaneous separate or sequential use. The product is particularly suitable for treating immunoregulatory disorder such as organ transplant rejection or graft rejection. While antibody to tumour necrosis factor or antibody to interferon-η alone have little or no effect on rejection, the combination of antibodies produces a surprising prolongation of graft or transplant survival.</p> |
